J&J, Pfizer To Gain As India Fast Tracks COVID-19 Vaccines Approved By Other Regulators
Supplies A Concern, Private Sales Likely
J&J and Pfizer should benefit from India’s unusual move to grant accelerated approvals minus a prior local bridging study for COVID-19 vaccines granted emergency use authorizations by certain regulators or on the WHO’s emergency use list. But while this seems like a prelude to permitting private sales, where will the supplies come from?
